V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330006093 | 330002894 | 1.65 | 10.7 | Curative (C) | 2013-07-07 | 2013-07-19 | CHOP R - 21 days | N | N | 330020816 | PEMBROLIZUMAB |
| 330006094 | 330002895 | null | 80.05 | Palliative (P) | 2016-02-09 | 2016-02-15 | Dacarbazine | null | null | 330020823 | DOXORUBICIN + IFOSFAMIDE |
| 330006095 | 330002895 | 1.7 | 12.4 | Curative (C) | 2017-05-14 | 2017-05-30 | CAPECITABINE + CARBOPLATIN + Cetuximab | N | N | 330020823 | FCR |
| 330006096 | 330010118 | null | null | Curative (C) | 2018-02-07 | 2018-02-07 | VIDE | N | null | 330020918 | ETOPOSIDE + IFOSFAMIDE |
| 330006097 | 330010118 | 1.7 | 49 | Palliative (P) | 2019-04-23 | 2019-04-24 | Vincristine (weekly) | 2 | N | 330020918 | FLUOROURACIL + MITOMYCIN |
| 330006098 | 330002896 | 1.83 | null | Curative (C) | 2016-05-06 | 2016-05-07 | BCG Intravesical | Y | N | 330020986 | AML18 TRIAL |
| 330006099 | 330002897 | 1.75 | 85.8 | Curative (C) | 2017-07-28 | 2017-07-28 | Chlorambucil | 02 | N | 330021072 | VIDE |
| 330006100 | 330002898 | 1.6 | 95 | Palliative (P) | 2015-09-03 | 2015-09-03 | Cisplatin + Vinorelbine (PO) | 02 | N | 330021091 | CAPECITABINE |
| 330006101 | 330002899 | 1.55 | 74.65 | Palliative (P) | 2014-12-05 | 2014-12-05 | Carboplatin + Vinorelbine IV &PO D8 | 02 | N | 330021094 | IMATINIB |
| 330006102 | 330007558 | 1.86 | 57.7 | Curative (C) | 2014-06-01 | 2014-07-07 | Capecitabine (14 days)+Carboplatin | 02 | null | 330021193 | CARBOPLATIN + RT |
| 330006103 | 330010119 | 1.77 | 0 | Palliative (P) | 2017-08-09 | 2017-08-16 | Azacitidine | 2 | N | 330021306 | BUSULFAN + FLUDARABINE + METHOTREXATE |
| 330006104 | 330010119 | null | 90.8 | Curative (C) | 2018-02-08 | 2018-02-08 | Paclitaxel 7 day | N | N | 330021306 | ACE (GERM CELL) |
| 330006105 | 330010119 | null | 50.9 | Curative (C) | null | 2016-03-31 | AML Int Guide ADE 8+3+5 (2) | N | N | 330021306 | CISPLATIN + DOX + ETOPOSIDE |
| 330006106 | 330010119 | 1.69 | 62.1 | Disease modification (D) | 2016-08-08 | 2016-08-08 | VAC | null | N | 330021306 | CAV |
| 330006107 | 330002900 | 1.8 | 48 | null | 2013-12-12 | 2014-01-06 | Cisplatin + Vinorelbine (IV) | N | N | 330021462 | VIDE |
| 330006108 | 330002900 | 1.71 | 58.35 | Adjuvant (A) | 2015-06-09 | 2015-06-14 | Bevacizumab 7.5mg/kg | 02 | N | 330021462 | CHOP R |
| 330006109 | 330002901 | 1.75 | 88.4 | Curative (C) | null | 2016-07-02 | NB BEACON Temoz Irin Bev | null | null | 330021497 | AZACITIDINE |
| 330006110 | 330007560 | 2 | 94.5 | Palliative (P) | 2016-05-11 | 2016-05-21 | Vemurafenib | N | N | 330021531 | BEP |
| 330006111 | 330002902 | null | 73.3 | Curative (C) | 2013-07-10 | 2013-07-10 | CNS Low Grade Glioma Vinblastine | N | N | 330021539 | IMATINIB |
| 330006112 | 330002903 | 0 | 20.9 | Curative (C) | 2017-11-20 | 2017-12-15 | Doxorubicin + Ifosfamide | N | N | 330021565 | EMA/CO |
| 330006113 | 330007561 | 1.62 | 90.2 | null | 2017-02-26 | 2017-02-26 | OCTREOTIDE | N | null | 330021705 | TEMOZOLOMIDE |
| 330006114 | 330010120 | null | 90.6 | Curative (C) | null | 2016-11-03 | Paclitaxel 7 day | null | null | 330021714 | VEPEMB |
| 330006115 | 330002904 | 1.67 | 111 | Curative (C) | 2015-06-09 | 2015-07-07 | EpSSG NRSTS 2005 | 2 | Y | 330021733 | PACLITAXEL |
| 330006116 | 330002904 | null | 83.7 | Palliative (P) | 2018-04-13 | 2018-04-29 | TEMOZOLOMIDE | 01 | N | 330021733 | CISPLATIN + DOXORUBICIN + METHOTREXATE |
| 330006117 | 330002904 | 0 | 51.2 | Palliative (P) | 2017-11-25 | 2017-12-04 | Vincristine (weekly) | 02 | N | 330021733 | CISPLATIN + VINORELBINE |
| 330006118 | 330002904 | 1.64 | null | Palliative (P) | 2017-10-23 | 2017-11-04 | FCR Oral - Cycle 1 | 02 | null | 330021733 | FLUOROURACIL + MITOMYCIN + RT |
| 330006119 | 330002905 | 1.74 | 68.8 | Neo-adjuvant (N) | 2013-11-20 | 2013-12-03 | Capecitabine (21days) + Carboplatin | N | N | 330022480 | BEP |
| 330006120 | 330002905 | 1.9 | 73 | Adjuvant (A) | 2016-10-31 | 2016-11-06 | Docetaxel | N | N | 330022480 | RUXOLITINIB |
| 330006121 | 330002906 | null | null | Disease modification (D) | 2016-11-19 | 2016-12-10 | IVA | N | N | 330022920 | EDP + MITOTANE |
| 330006122 | 330007564 | 1.62 | 86.3 | Disease modification (D) | 2016-04-04 | 2016-04-09 | OST Euramos 1 Closed Trial - M | N | N | 330023337 | PEMBROLIZUMAB |
| 330006123 | 330002907 | 0 | 65 | Palliative (P) | 2016-04-14 | 2016-04-14 | Midostaurin | 02 | N | 330023398 | CVD |
| 330006124 | 330002908 | 1.67 | 63 | Palliative (P) | 2017-01-09 | 2017-01-23 | Capecitabine (21days) + Carboplatin | N | N | 330023399 | METHOTREXATE |
| 330006125 | 330002909 | 1.6 | 76.8 | Curative (C) | 2015-02-26 | 2015-03-18 | BCG Intravesical | N | Y | 330023588 | FLAG + IDARUBICIN |
| 330006126 | 330002910 | 1.81 | 89.3 | Curative (C) | null | 2016-10-07 | Mitotane 4 - 4.5g | null | null | 330023936 | MITOTANE |
| 330006127 | 330007565 | 1.78 | 62 | Adjuvant (A) | 2017-10-24 | 2017-11-24 | Hydroxycarbamide | N | Y | 330024068 | AZACITIDINE |
| 330006128 | 330002911 | 1.73 | 81.5 | Curative (C) | 2014-10-31 | 2014-10-31 | VeIP | 02 | N | 330024216 | VINCRISTINE |
| 330006129 | 330002911 | 1.75 | 77.1 | Disease modification (D) | 2018-02-18 | 2018-02-20 | Methotrexate + Folinic acid | 02 | N | 330024216 | CISPLATIN + FLUOROURACIL + RT |
| 330006130 | 330002911 | 1.56 | 60.4 | Palliative (P) | 2015-10-22 | 2015-11-04 | CHOP R - 21 days | N | N | 330024216 | PEMBROLIZUMAB |
| 330006131 | 330002912 | 0 | 69.1 | Palliative (P) | 2015-12-15 | 2015-12-24 | Doxorubicin + Ifosfamide | N | N | 330024623 | BEP |
| 330006132 | 330002913 | 1.6 | null | null | 2017-11-22 | 2017-11-23 | Capecitabine | N | N | 330024633 | CISPLATIN + TOPOTECAN |
| 330006133 | 330002914 | 1.7 | 14 | Palliative (P) | 2017-06-14 | 2017-06-26 | AML16 DA 3+10 | N | Y | 330024751 | AZACITIDINE |
| 330006134 | 330002915 | 1.6 | null | Palliative (P) | 2018-07-17 | 2018-07-17 | Temozolomide + RT | Y | N | 330024781 | VIDE |
| 330006135 | 330002915 | 1.74 | 63.5 | Curative (C) | 2016-12-06 | 2016-12-06 | OST Euramos 1 Closed Trial - M | 2 | N | 330024781 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 330006136 | 330002915 | 1.69 | 74.4 | null | 2017-06-11 | 2017-06-12 | Bortezomib (weekly) | 02 | null | 330024781 | CAPECITABINE + MITOMYCIN + RT |
| 330006137 | 330002915 | 1.81 | 0 | Palliative (P) | 2017-09-22 | 2017-09-22 | BLEOMYCIN | 2 | N | 330024781 | DOCETAXEL |
| 330006138 | 330002916 | 1.61 | 104.1 | Palliative (P) | 2017-08-06 | 2017-08-06 | CAPECITABINE + OXALIPLATIN | 02 | N | 330003175 | DHAP - R |
| 330006139 | 330002917 | 1.6 | 94 | Palliative (P) | 2017-06-19 | 2017-06-21 | ECX | N | N | 330003882 | METHOTREXATE INTRATHECAL |
| 330006140 | 330002917 | 1.77 | 0 | Palliative (P) | 2017-12-13 | 2018-01-01 | Gemcitabine day 1&8 | N | N | 330003882 | PEMBROLIZUMAB |
| 330006141 | 330002918 | null | 71.1 | Curative (C) | 2018-10-21 | 2018-11-04 | Imatinib 400mg | N | N | 330006301 | BEVACIZUMAB |
| 330006142 | 330002918 | 1.83 | null | Palliative (P) | 2017-02-05 | 2017-03-31 | CVP | N | N | 330006301 | AZACITIDINE |